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ABSTRACT
A variant within the gene locus encoding PTPN22 (protein tyrosine phosphatase, non-receptor type 22)
emerged as an important risk factor for auto-inﬂammatory disorders, including rheumatoid arthritis,
systemic lupus erythematosus and type 1 diabetes, but at the same time protects from Crohn disease, one
of the 2 main forms of inﬂammatory bowel diseases. We have previously shown that loss of PTPN22
results in decreased NLRP3 (NLR family pyrin domain containing 3) activation and that this effect is
mediated via enhanced NLRP3 phosphorylation. However, it is unclear how phosphorylation of NLRP3
mediates its inhibition. Here, we demonstrate that loss of macroautophagy/autophagy abrogates the
inhibitory effect on NLRP3 activation observed upon loss of PTPN22. Phosphorylated, but not
nonphosphorylated NLRP3 is found in autophagosomes, indicating that NLRP3 phosphorylation mediates
its inactivation via promoting sequestration into phagophores, the precursors to autophagosomes. This
ﬁnding shows that autophagy and NLRP3 inﬂammasome activation are connected, and that PTPN22 plays
a key role in the regulation of those 2 pathways. Given its role in inﬂammatory disorders, PTPN22 might be
an attractive therapeutic target, and understanding the cellular mechanisms modulated by PTPN22 is of
crucial importance.
KEYWORDS
inﬂammasome; Lyp; NLRP3;
NOD-like receptor protein;
PEST-enriched phosphatase;
SQSTM1; tyrosine
phosphorylation
Introduction
Inﬂammasomes are multiprotein aggregates that form upon
intracellular presence of damage-associated molecular patterns
(DAMPs), and typically consist of 3 core components: (1) a
receptor protein that initiates inﬂammasome assembly upon
activation, (2) the adaptor protein PYCARD/ASC (PYD and
CARD domain containing; not present in some inﬂamma-
some-complexes), and (3) the protease CASP1/caspase-1. Once
assembled, inﬂammasomes mediate the cleavage of pro-CASP1
into its active form. Active CASP1 in turn cleaves the precur-
sors of several inﬂammatory molecules, including IL1B (inter-
leukin 1 b) and IL18 (interleukin 18) into their active forms.1
One of the best studied inﬂammasome receptors is NLRP3
(NLR family pyrin domain containing 3), which responds to
several damage- and pathogen-associated molecules, including
bacterial products, such as muramyl dipeptide (MDP)2 or Liste-
ria toxin,3 particulate materials (e.g., silicium dioxide, titanium
dioxide, monosodium crystals)4,5 as well as changes in intracel-
lular potassium levels and increased levels of reactive oxygen
species.6,7 Due to the potent pro-inﬂammatory response upon
IL1B and IL18 release, inﬂammasome-inducing receptors and
subsequent formation of inﬂammasome complexes is tightly
regulated. Since NLRP3 responds to such a wide range of acti-
vators, control of NLRP3 activation is of special importance. In
addition to its restricted expression, and polyubiquitination
that mediates NLRP3 degradation via the proteasome,8 we have
recently found that NLRP3 activation is negatively regulated by
tyrosine phosphorylation.9 However the exact mechanism by
which phosphorylation of NLRP3 interferes with its ability to
form inﬂammasome-complexes is still unknown.
The phosphatase responsible for dephosphorylation and
subsequently robust activation of NLRP3 upon the presence of
danger molecules is PTPN22/PEP/Lyp (protein tyrosine phos-
phatase, nonreceptor type 22).9 While loss of PTPN22 results
in decreased NLRP3-mediated IL1B secretion, presence of a
variant in the gene encoding PTPN22 promotes inﬂammasome
activity.9 This variant has been associated with increased risk to
develop several chronic inﬂammatory disorders, including
rheumatoid arthritis (RA)10,11 systemic lupus erythematosus
(SLE)12-15 and type I diabetes, but at the same time is negatively
associated with the onset of Crohn disease (CD), one subform
of inﬂammatory bowel disease (IBD).16,17 PTPN22 is not only
involved in inﬂammasome-activation, but also exerts other
prominent functions such as regulating the response to type I
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interferons,18,19 and negative regulation of T cell receptor sig-
naling cascades.20-22 We have further shown that PTPN22
expression is decreased in intestinal tissue of CD patients and
interferes with MDP-induced autophagy.23,24
Autophagy is an important cellular process that mediates
bulk degradation of damaged/dysfunctional proteins and
organelles in the cytosol.25,26 In addition, autophagy is critically
involved in degradation and removal of invading bacteria27-29
making it a pivotal player in intestinal homeostasis.27,30-32
Genetic variants in molecules involved in the autophagy
machinery, such as ATG16L1 (autophagy-related 16 like 1)33
and IRGM (immunity-related GTPase M)17,34 increase the risk
to develop IBD. Further, there is evidence that autophagy might
be involved in the control of IL1B secretion.35-37
The aim of this study was to investigate whether PTPN22
interferes with cellular pathways inﬂuencing NLRP3 activation.
Since PTPN22 controls autophagy, and autophagy controls
IL1B secretion, the focus was to address whether PTPN22
mediates its control on NLRP3 activation in an autophagy-
dependent manner.
Results
Inhibition of autophagy results in increased IL1B secretion
in both PTPN22 competent and PTPN22-deﬁcient cells
Because we have previously shown that loss of PTPN22
results in enhanced levels of autophagy,23 and autophagy
has been implicated in the regulation of IL1B secretion35-37
we ﬁrst addressed whether autophagy plays a role in the
reduction of IL1B secretion observed upon loss of PTPN22.
Therefore, THP-1 cells expressing either control or
PTPN22-targeting shRNA, were treated with the autophagy
inhibitors 3-methyladenine (3-MA), baﬁlomycin A1, or the
phosphatidylinositol 3-kinase inhibitor wortmannin before
treatment with MDP, a pathogen-associated molecular pat-
tern (PAMP) that induces autophagy as well as the secre-
tion of IL1B. As expected, loss of PTPN22 resulted in
enhanced autophagy as observed by increased MAP1LC3B/
LC3B (microtubule associated protein 1 light chain 3 b)-II
accumulation, but impaired secretion of IL1B (Fig. 1A, B).
Of note, loss of PTPN22 did not affect protein expression
of pro-IL1B (Fig. 1A). Inhibition of autophagy using 3-MA,
wortmannin, or baﬁlomycin A1 promoted secretion of IL1B
in both PTPN22-competent and PTPN22-deﬁcient cells
(Fig. 1B). When autophagy was inhibited, PTPN22-deﬁcient
cells secreted as much IL1B as PTPN22-competent cells
(Fig. 1B). The effects on IL1B secretion were due to differ-
ences in inﬂammasome activation: levels of cleaved CASP1
were decreased in PTPN22-deﬁcient cells, but enhanced in
cells where autophagy was inhibited (Fig. 1A). Similar
results were obtained in bone marrow-derived dendritic
cells (BMDC) from either wild-type (WT) or Ptpn22-deﬁ-
cient (ptpn22¡/¡) mice (Fig. 1C, D), and when monosodium
urate (MSU) or ATP were used as inﬂammasome activators
(Fig. S1): whereas PTPN22-deﬁcient BMDC secreted
reduced levels of IL1B compared with WT cells, this effect
was abrogated upon inhibition of autophagy using 3-MA,
wortmannin or baﬁlomycin A1 (Fig. 1C, D, Fig. S1).
To conﬁrm this ﬁnding, we next used nontargeting control
siRNA or siRNA constructs speciﬁc for ATG16L1/Atg16l1, a
molecule essential for autophagy induction. Again, inhibition
of functional autophagy resulted in enhanced cleavage of
CASP1 and enhanced IL1B secretion in both PTPN22-compe-
tent and PTPN22-deﬁcient cells (Fig. 2A, B and Fig. S2A, B,
Fig. S3A). Interestingly, the reduction in CASP1 cleavage and
IL1B secretion observed upon loss of PTPN22 was no longer
present when autophagy was blocked (Fig. 2A, B, Fig. S2A, B,
Fig. S3A). Again, these effects were similar in cells treated with
MSU (Fig. 2) or with MDP (Fig. S2, Fig. S3). Similar ﬁndings
were obtained when we silenced LC3B/Lc3b (Fig. 2C, D,
Fig. S2C, D, Fig. S3B), although cells lacking LC3B are not
completely deﬁcient in autophagy due to the presence of other
LC3 isoforms. However, silencing of LC3B/Lc3b clearly reduced
autophagy as indicated by enhanced levels of SQSTM1/p62
(sequestosome 1), a molecule degraded via autophagy. Taken
together, these data strongly indicate a role for autophagy in
the reduction of IL1B secretion and inﬂammasome activation
observed in PTPN22-deﬁcient cells.
NLRP3 is found in autophagosomes upon
inﬂammasome activation
We have previously shown that loss of PTPN22 results in
enhanced phosphorylation of NLRP3, and that phosphoryla-
tion of NLRP3 results in decreased inﬂammasome activity. To
test how autophagy might affect phosphorylated NLRP3, we
analyzed whether NLRP3 is present in autophagosomes, and
whether this is dependent on its phosphorylation status. To
this end, we enriched autophagosomes37,38 from MDP- or
MSU-treated THP-1 cells or BMDC and probed for NLRP3.
While in untreated cells only a faint NLRP3 band was detect-
able in the autophagosome-enriched fraction, NLRP3 was read-
ily detectable in autophagosomes of MDP- or MSU-treated
cells (Fig. 3A, Fig. S4A, B). Of note, in cells lacking PTPN22,
more NLRP3 was present in the autophagosome-enriched frac-
tion upon NLRP3 activation (Fig. 3A). This was clearly an
effect resulting from the lack of PTPN22 phosphatase function,
because the same effect was observed in cells that express a
loss-of-function variant in PTPN2213 (Fig. S4B). We also
detected PYCARD/ASC, but not CASP1 or IL1B in autophago-
somes upon inﬂammasome activation (Fig. 3A, Fig. S4B).
Localization of NLRP3 in autophagosomes was conﬁrmed
by confocal microscopy of cells costained for NLRP3 and
LC3B. While in cells without inﬂammasome activation, NLRP3
was found all over the cytosol, activation of NLRP3 with MSU
resulted in NLRP3 aggregation. Some of these NLRP3 aggre-
gates colocalized with LC3B puncta, indicating that they were
recruited to phagophores (Fig. 3B; left panel). NLRP3 was not
only recruited into phagophores, but was also found in lyso-
somes upon NLRP3 activation, indicating that it is degraded in
autolysosomes (Fig. 3B; right panel). In ptpn22¡/¡ cells, or cells
expressing the loss-of-function Ptpn22 variant, more LC3B
puncta were observed in nontreated cells, and, upon activation
with MSU, more NLRP3 aggregates colocalized with LC3B
puncta. Conversely, cells expressing an altered function Ptpn22
variant, which results in a gain of function in terms of NLRP3
AUTOPHAGY 1591
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Figure 1. Reduction of IL1B secretion upon loss of PTPN22 is not observed in autophagy-deﬁcient cells. PMA-differentiated THP-1 cells expressing either control, or
PTPN22-speciﬁc shRNA (A and B), and BMDC from wild-type (WT) or PTPN22 deﬁcient (ptpn22¡/¡) mice (C and D) were treated with 3-MA (1 mM), (Wortm; 10 uM), or
baﬁlomycin A1 (Baﬁlo; 100 nM) to inhibit autophagy, 1 h before treatment with muramyl dipeptide (MDP, 100 ng/ml) for 24 h. The graphs show (A)and (C): representative
western blot pictures of the indicated proteins and (B and D): results from IL1B ELISA. Data are representative for 1 out of 3 independent experiments with 3 replicates
(n D 3). Numbers below the western blot pictures show results of densitometric measurements.  D p < 0.05, n.s. D not signiﬁcant, one-way ANOVA with Bonferroni
correction.
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regulation,9 NLRP3 was not present in autophagosomes
(Fig. 3C).
Only phosphorylated NLRP3 is detected
in autophagosomes
We next precipitated NLRP3 from autophagosome-enriched
fractions or whole cell lysates and probed for phospho-tyrosine
(p-Tyr). Interestingly, in autophagosomes, p-Tyr was increased
upon MSU-treatment, whereas in whole cell lysates it was
decreased (Fig. 3D). In ptpn22¡/¡ cells, we found no decrease in
NLRP3 tyrosine phosphorylation upon inﬂammasome activation,
and clearly more NLRP3 was present in autophagosomes
(Fig. 3A). Since similar ﬁndings were observed in cells expressing
a loss-of-function PTPN22 variant (Fig. S4C), this effect seems
to be due to a loss of PTPN22 function, rather than absence of
the protein per se. This ﬁnding strongly indicates that upon
MDP- or MSU-treatment, phosphorylated NLRP3 is sequestered
into phagophores. To address whether nonphosphorylated
NLRP3 is also present in autophagosomes, we next ran whole
cell lysate and autophagosome-enriched fractions on a Phos-tag
gel (Fig. 3E). On these gels, phosphorylated proteins migrate at a
slower speed than their nonphosphorylated forms.39 In the lysate
of nontreated cells, NLRP3 appeared as a double band with
approximately 50% appearing in the upper (phosphorylated) and
50% in the lower (nonphosphorylated) band. This is consistent
with our previous ﬁndings that roughly half of NLRP3 is phos-
phorylated in nonactivated cells.9 In lysates, phosphorylation was
decreased upon MDP treatment, where only a faint upper (phos-
phorylated) band was detectable. Of note, in ptpn22¡/¡ cells or
cells expressing a loss-of-function variant in Ptpn22 (263Q),
MSU treatment did not decrease phosphorylation of NLRP3.
Furthermore, in autophagosomes, the lower, nonphosphorylated
band was not visible (Fig. 3E), indicating that only phosphory-
lated NLRP3 was sequestered into phagophores.
NLRP3 lacking the phosphorylation site is not recruited
to phagophores
To further test the hypothesis that phosphorylation of NLRP3
is required for its recruitment into phagophores, we transfected
BMDC from NLRP3-deﬁcient mice with either wild-type
NLRP3 or a mutated form of NLRP3 that lacks the phosphory-
lation site at tyrosine 859 (Y859F NLRP3). When analyzing
autophagosome-enriched fractions for the presence of NLRP3,
we only found NLRP3 in autophagosomes from BMDC trans-
fected with WT NLRP3, but not in cells transfected with
NLRP3Y859F, which lacks the phosphorylation site (Fig. 4A,
Figure 2. Knockdown of LC3B or ATG16L1 abrogates the reduction in IL1B secretion observed in PTPN22-deﬁcient cells. BMDC from WT or ptpn22¡/¡ mice were treated
with nontargeting control siRNA or siRNA speciﬁc for Atg16l1 (A and B) or Lc3b (C and D) 48 h before priming with ultra-pure lipopolysaccharide (upLPS) (16 h) and subse-
quent activation with MSU (150 mg/ml) for 6 h. The graphs show (A and C): representative western blots from cell lysates for the indicated proteins; and (B and D): IL1B
ELISA and western blot analysis from cell culture supernatants. Data are representative for 1 out of 3 independent experiments with 3 replicates (n D 3). Numbers below
the western blot pictures show results of densitometric measurements.  D p < 0.05,  D p < 0.01; one-way ANOVA with Bonferroni correction.
AUTOPHAGY 1593
D
ow
nl
oa
de
d 
by
 [U
ZH
 H
au
ptb
ibl
iot
he
k /
 Z
en
tra
lbi
bli
oth
ek
 Z
ür
ich
] a
t 0
8:3
1 1
0 J
an
ua
ry
 20
18
 
Fig. S5A). In cells transfected with NLRP3Y859F, no colocaliza-
tion of LC3B puncta with NLRP3 aggregates was observed
(Fig. 4B). This further indicates that phosphorylated NLRP3—
but not nonphosphorylated NLRP3—is sequestered to the
phagophore upon inﬂammasome induction. Of interest, pres-
ence of the NLRP3Y859F construct resulted in increased CASP1
cleavage and enhanced IL1B secretion upon MSU and MDP
treatment (Fig. 4C, Fig. S5). This observation indicates that
phosphorylation of NLRP3 and subsequent degradation via
autophagy is a regulatory mechanism of NLRP3 activation. In
summary, these data indicate that NLRP3 phosphorylation
results in sequestering of NLRP3 into phagophores and that
this might be the mechanism for how phosphorylation of
NLRP3 reduces its activation.
Phosphorylated NLRP3 interacts with SQSTM1
upon inﬂammasome activation
To understand how phosphorylated NLRP3 is recruited into
phagophores we addressed whether NLRP3 interacts with
molecules involved in targeting substrates to the phagophore.
Indeed, we found that NLRP3 interacts with SQSTM1 upon
inﬂammasome activation (Fig. 5A). Of note, this interaction
was strictly dependent on phosphorylation of NLRP3, because
in cells lacking the phosphorylation site no interaction between
SQSTM1 and NLRP3 was observed. On the other hand, a phos-
pho-mimetic variant of NLRP3 (NLRP3Y859E; reported in
Ref. 9) resulted in increased interaction between SQSTM1 and
NLRP3 (Fig. 5A). Further, loss of PTPN22 resulted in increased
interaction of SQSTM1 and NLRP3 (Fig. 5B).
NLRP3 does not interact with SQSTM1
in PYCARD-deﬁcient cells
So far we showed that phosphorylated NLRP3 interacts with
SQSTM1; however, this is only the case when NLRP3 is acti-
vated. Because a portion of NLRP3 is phosphorylated in the
steady-state, we wondered why phosphorylated NLRP3 is not
recruited to phagophores in resting cells. Because NLRP3 acti-
vation results in its interaction with PYCARD, and we also
Figure 3. Phosphorylated NLRP3 is found in autophagosomes. (A) BMDC were primed for 16 h with upLPS to induce induction of NLRP3 and IL1B expression, before treat-
ment with MSU for 6 h. The pictures show representative western blots from the indicated proteins in cell lysates and autophagosome-enriched fractions as indicated. (B)
Confocal microscopy of THP-1 cells treated with LPS, or LPS and MSU, immunostained for NLRP3 (green) and LC3B (red; left side of the ﬁgure) or immunostained for
NLRP3 (green) and the lysosome marker LAMP1 (red; right side of the ﬁgure); below and beside the image: z-stack at position of the arrows. scale bars: 10 mm. P-Tyr
stands for phospho-tyrosine. (C) BMDC from WT mice, ptpn22¡/¡ mice or mice expressing a gain-of-function variant in Ptpn22 (619W) were treated as in (A) and immu-
nostained for NLRP3 (green) and LC3B (red). (D) BMDC from WT or ptpn22¡/¡ mice were treated as in (A) and NLRP3 precipitated from either cell lysates or autophago-
some-enriched fractions. The pictures show representative western blots for phospho-tyrosine (p-Tyr) and NLRP3 run in conventional SDS-PAGE. (E) control-transfected
WT BMDC, control-transfected ptpn22¡/¡ BMDC, or ptpn22¡/¡ BMDC transfected with a vector expressing a loss-of-function variant in ptpn22 (263Q) were treated as in
(A) and lysates run on Phos-tag gels, which allow the separation of phosphorylated from nonphosphorylated proteins due to slower migration of the phosphorylated
forms. Data are representative for 1 out of 3 independent experiments with 3 replicates each (nD 3), except for confocal microscopy, where the experiment has been per-
formed only twice with 3 replicates. Images are representative for at least 5 scanned areas for each depicted condition. Scale bars: 10 mm. P-Tyr stands for phospho-tyro-
sine. Numbers below the western blot pictures show results of densitometric measurements.
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found PYCARD in autophagosomes, we next addressed
whether the interaction of NLRP3 with SQSTM1 is PYCARD
dependent. When we treated PYCARD-deﬁcient BMDC with
MSU, we did not detect NLRP3 in autophagosomes (Fig. 6A,
B). Immunoprecipitation of NLRP3 revealed that NLRP3 was
phosphorylated in pycard¡/¡ cells, but it did not interact with
SQSTM1 (Fig. 6C). This result indicates that the interaction of
NLRP3 with SQSTM1 was dependent on NLRP3-PYCARD
interaction. In sum, our results indicate that phosphorylated
NLRP3 binds SQSTM1 and is subsequently recruited into
phagophores, once it interacts with PYCARD. Upon NLRP3
activation, PTPN22 dephosphorylates NLRP3 and thereby pro-
tects it from degradation, allowing robust inﬂammasome activ-
ity (summarized in Fig. S6).
Discussion
We have previously demonstrated that loss of PTPN22 reduces
IL1B secretion via enhanced phosphorylation of the inﬂamma-
some receptor NLRP3.9 Here, we demonstrate that loss of func-
tional autophagy abrogates the reduction of NLRP3 activation
observed in PTPN22-deﬁcient cells. This effect is explained by
our observation that phosphorylation of NLRP3 mediates
recruitment of NLRP3 into phagophores, which seems to be
responsible for reduced NLRP3 activity. Our data clearly show
that in autophagy-deﬁcient cells phosphorylated NLRP3 is still
able to efﬁciently form inﬂammasome complexes, most likely
due to the lack of sequestration into phagophores. In turn,
dephosphorylation of NLRP3—as observed upon robust
inﬂammasome induction—protects NLRP3 from being seques-
tered into phagophores, and allows full NLRP3 activation.
Autophagy and inﬂammasome activation both play a crucial
role in the development of several inﬂammatory disorders,
including neurodegenerative diseases, cancer, rheumatoid
arthritis, multiple sclerosis, IBD, and many more (reviewed in
refs. 40-42); hence, understanding the mechanisms for how
these pathways inﬂuence each other is of great relevance for
understanding underlying pathomechanisms, and ultimately
for the development of novel therapeutic strategies. In the
intestines, autophagy plays a crucial role for tissue homeostasis
and defense against invading bacteria.27,30 This role is
highlighted by the fact that genetic variants resulting in defects
in the autophagy machinery enhance the risk to develop
IBD.17,33,43 Although rather protective in many cells and
Figure 4. NLRP3 lacking the phosphorylation site is not recruited to phagophores. BMDC from nlrp3¡/¡mice were transfected with a wild-type (WT) Nlrp3 expression vec-
tor, or a Nlrp3 construct where Tyr859 in NLRP3 is replaced with a phenylalanine (Y859F; Y>F) to abolish NLRP3 phosphorylation. The cells were primed for 16 h with
upLPS to induce NLRP3 and IL1B expression, before activation with MSU (150 mg/ml) for 6 h. Shown is (A) representative western blot pictures from cell lysates and auto-
phagosome-enriched fractions, (B) confocal microscopy of LC3B (red) and NLRP3 (green) immunostained cells; blue: DNA stained with DAPI, scale bar: 10 mm; and (C)
IL1B in the cell culture supernatant. Data are representative for 1 out of 3 independent experiments with 3 replicates each (n D 3), except for confocal microscopy where
the experiment has been performed only twice with 3 replicates. Images are representative for at least 5 scanned areas for each depicted condition. Numbers below the
western blot pictures show results of densitometric measurements.  D p < 0.05, one-way ANOVA with Bonferroni correction.
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diseases, in some disorders autophagy might also drive patholo-
gies: Enhanced autophagy promotes survival of inﬂammatory
synovial ﬁbroblasts in rheumatoid arthritis,44 and protects can-
cer cells from cell death.45 For the NLRP3 inﬂammasome the
situation is a little different: in classical inﬂammatory disorders,
such as arthritis, diabetes, or SLE, an increase of NLRP3 activa-
tion clearly promotes disease onset/progression.46-49 In the
intestine, however, the role of NLRP3 is still a matter of dispute,
with some reports showing protective effects upon loss of
NLRP3, whereas others demonstrate that NLRP3-induced
inﬂammasome activation is important for promoting wound
healing and tissue repair.50-52
Although there is evidence that autophagy is involved in
mediating unconventional secretion of inﬂammasome sub-
strates,53 several reports show that loss of functional autophagy
results in enhanced inﬂammasome activation.35-37 One mecha-
nism proposed to mediate this effect is the accumulation of
aged mitochondria upon loss of autophagy,54 and subsequently
enhanced levels of reactive oxygen species in the cytosol, which
induces inﬂammasome activity.55
Autophagy also controls inﬂammasome activation directly:
ubiquitinated inﬂammasomes37 as well as IL1B35 can be found
in autophagosomes. We demonstrate here an additional mech-
anism—how autophagy affects NLRP3-mediated IL1B secre-
tion, which is dependent on the recruitment of phosphorylated
NLRP3 into phagophores. Thereby, phosphorylation of NLRP3
mediates its interaction with SQSTM1 and subsequent accumu-
lation in autophagosomes upon inﬂammasome activation;
hence autophagy removes NLRP3 from the cytosol and thereby
directly reduces NLRP3-mediated inﬂammasome assembly.
Conversely, PTPN22-mediated dephosphorylation protects
NLRP3 from recruitment into phagophores and thereby pro-
motes inﬂammasome activation. Consistent with this, we only
detected phosphorylated NLRP3 in autophagosomes, but not
nonphosphorylated NLRP3. These ﬁndings are well in line
with our previous results, where we observed that an increase
in NLRP3 phosphorylation in PTPN22-deﬁcient cells resulted
in a reduction of inﬂammasome activation.9
Of note, treatment with the NLRP3 activators MSU and
MDP did not promote protein expression levels of PTPN22;
Figure 5. NLRP3 interacts with SQSTM1 upon its activation. (A) BMDC from nlrp3¡/¡ mice were transfected with a wild-type (WT) Nlrp3 expression vector, a Nlrp3 con-
struct where Tyr859 in NLRP3 is replaced with a phenylalanine (Y859F; Y>F) to abolish NLRP3 phosphorylation, or with a phsopho-mimetic NLRP3, where Tyr859 was
replaced with a glutamate (Y859E; Y > E). The cells were primed for 16 h with upLPS to induce NLRP3 and IL1B expression, before activation with MSU (150 mg/ml) for
6 h. NLRP3 or SQSTM1 were precipitated from the lysate and probed for the indicated proteins. (B) BMDC from WT or ptpn22¡/¡ cells were primed for 16 h with upLPS
to induce NLRP3 and IL1B expression, before activation with MSU (150 mg/ml) for 6 h. NLRP3 or SQSTM1 were precipitated from the lysate and probed for the indicated
proteins. Data is representative for 1 out of 3 independent experiments with 3 replicates each (n D 3). Numbers below the western blot pictures show results of densito-
metric measurements.
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hence it might be surprising that PTPN22 has such a strong
impact on downstream signaling events induced by these 2
molcules. Nevertheless, we previously showed that signals,
which induce robust NLRP3 activation, also promote the inter-
action between NLRP3 and PTPN22,9 and increase the phos-
phatase activity of PTPN22.23
Further, we found that the recruitment of NLRP3 into phago-
phores was accompanied by the interaction of NLRP3 with
SQSTM1, a molecule that targets its binding partners to autopha-
gic degradation. We therefore speculate that the recruitment of
NLRP3 into phagophores is a result of NLRP3-SQSTM1 interac-
tion, which is induced upon inﬂammasome activation. We
observed an increase in autophagy in both MDP- and MSU-
treated cells; hence, sequestration of NLRP3 might also be the
result of enhanced autophagy, and not the result of inﬂamma-
some activation. Of interest, however, neither the interaction of
NLRP3 with SQSTM1 nor recruitment of NLRP3 into phago-
phores was observed in cells lacking PYCARD. Since NLRP3
only interacts with PYCARD upon inﬂammasome induction,
this strongly indicates that inﬂammasome activation is necessary
for the interaction of NLRP3 with SQSTM1, and subsequently
also for NLRP3 sequestration into phagophores.
Upon its activation, NLRP3 forms complexes that serve as a plat-
form for the induction of PYCARD aggregates, which then mediate
CASP1 activation.56 We speculate that phosphorylated NLRP3 is
less efﬁcient in promoting the formation of PYCARD specks, but
promotes binding with SQSTM1 in a PYCARD-dependent
manner. In a broader view, this would also be in linewith autophagy
as a mechanism to remove damaged/nonfunctional proteins from
the cytosol: if phosphorylated NLRP3 is less efﬁcient in promoting
PYCARD specks, it might be regarded as a nonfunctional protein.
Taken together, our results show that NLRP3 inﬂammasome
activation and autophagy are closely interweaved pathways,
and that PTPN22 crucially interferes with the function of these
2 pathways. In conclusion, our results explain the mechanism
for how phosphorylation of NLRP3 reduces its activation and
dampens secretion of IL1B, and why this effect is autophagy
dependent. Further, this explains how loss of PTPN22 and sub-
sequent enhanced NLRP3 phosphorylation mediate a decrease
in NLRP3 inﬂammasome activation. Together with previous
work from other groups, our ﬁndings in this and previous stud-
ies suggest that PTPN22 might be an interesting therapeutic
target for a broad number of inﬂammatory diseases. However,
given the important role of autophagy, it is obvious that under-
standing the molecular mechanism affected by PTPN22 in
more detail is of important relevance before the development
of possible treatment options.
Methods
Cell culture
THP-1 cells (DSMZ, ACC-16) were cultured in RPMI (Sigma-
Aldrich, R8758) supplemented with 10% fetal calf serum (FCS;
Figure 6. PYCARD is required for recruitment of NLRP3 into phagophores. BMDC from WT or pycard¡/¡ cells were primed for 16 h with upLPS to induce NLRP3 and IL1B
expression, before activation with MSU (150 mg/ml) for 6 h. (A) confocal microscopy of LC3B (red) and NLRP3 (green) immunostained cells; blue: DNA stained with DAPI,
scale bar: 10 mm. (B) Western blots from autophagosome-enriched fractions and lysates were probed for the indicated proteins. (C) NLRP3 or SQSTM1 were precipitated
from the lysate or from autophagosome-enriched fractions and probed for the indicated proteins. P-Tyr stands for phospho-tyrosine. Data are representative for 1 out of
3 independent experiments with 3 replicates each (n D 3), except for confocal microscopy where the experiment has been performed only once with 3 replicates. Images
are representative for at least 5 scanned areas for each depicted condition. Numbers below the western blot pictures show results of densitometric measurements.
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PAA Laboratories, P40–47100). Bone-marrow derived den-
dritic cells (BMDCs) were obtained as described previously.23
In brief, bone marrow was collected from femur and tibia of 8–
10-wk-old mice and cultured for 7 d in RPMI supplemented
with 10% FCS, 1% sodium pyruvate solution, 1% glutamine
(Sigma-Aldrich, G7513), and 25% of conditioned medium
from mouse- CSF2/GM-CSF-producing X63 hybridoma cells,
corresponding to 100 IU CSF2/ml. X63-mCSF2 cells were a
kind gift from E. Contassot (Clinic for Dermatology of the Uni-
versity Hospital Zurich, Zurich, Switzerland). ptpn22 heterozy-
gous mice were obtained from Genentech and bred with each
other to obtain WT and ptpn22¡/¡ littermates, pycard¡/¡ mice
were a gift from E. Contassot.
MDP, MSU, and ATP treatment
For experiments, THP-1 cells were seeded at a density of 1 £
106 cells/ml and differentiated into macrophages using 100 mg/
ml PMA (Sigma-Aldrich, P1585) for 48 h. Medium was
changed to serum-free medium 6 h before transfection with
MDP (100 ng/ml; InvivoGen, tlrl-mdpc), or to serum-free
medium containing ultrapure lipopolysaccharide (upLPS, 100
ng/ml; InvivoGen, tlrl-3pelps) 16 h before treatment with MSU
(150 mg/ml; InvivoGen, tlrl-msu) or ATP (2 mM; InvivoGen
tlrl-atp). For transfection, MDP (InvivoGen, tlrl-mdpc) was
dissolved in DMSO and mixed with Lipofectamine (Invivo-
Gen, L3000–001) for 15 min before applying to the cell culture
media. As a control, DSMO mixed with Lipofectamine was
used. MSU and ATP were applied onto the cells as suspensions.
Likewise, BMDCs were collected at d 7 of BM cultures in differ-
entiation medium, and seeded in new plates (0.5 £ 106 cells/
well in 12-well plates) in RPMI supplemented with 10% FCS.
After 6 h, medium was changed for serum-free medium 6 h
before transfection with MDP or treatment with MSU or ATP
as described above.
Inhibitors, shRNA, and siRNA treatment
For experiments with inhibitors, cells were plated in serum-free
medium 12 h before incubation with 3-MA (10 mM; Sigma-
Aldrich, M9281), wortmannin (10 mM; Sigma-Aldrich, 95455),
or baﬁlomycin A1 (100 nM; Sigma-Aldrich, B1793) for 1 h
before treatment with MDP (100 ng/ml; InvivoGen, tlrl-mdpc),
MSU (150 mg/ml; InvivoGen, tlrl-msu) or ATP (2 mM; Invivo-
Gen, tlrl-atp). Knockdown of PTPN22 was induced in THP-1
cells using lentiviral particles containing PTPN22-speciﬁc
shRNA as described previously.23 For knockdown of LC3B and
ATG16L1 3 different silencer predesigned siRNA oligonucleoti-
des targeting LC3B or ATG16L1 mRNA, respectively, were
obtained from Life Technologies (AM16708A, IDs 44451,
44268, 44361 for ATG16L1 and IDs 30209, 30304, 130443 for
LC3B). Per transfection, 100 pmol of each of the 3 gene-speciﬁc
siRNA oligonucleotides were used. A nonspeciﬁc control
siRNA SMARTpool (Life Technologies, AM16708A) at a con-
centration of 100 pmol per transfection was used as negative
control. THP-1 cells were transfected using the Amaxa nucle-
ofector system (Lonza, AAB-1001) according to the manufac-
turer’s instructions. After transfection, THP-1 cells were
cultured in a 24-well plate for 48 h in RPMI supplemented with
10% FCS. For transfection of BMDC, siRNA was mixed with
Lipofectamine RNAiMAX (Life Technologies, 13778150) for
15 min before adding to the cell culture media. After 6 h,
medium was changed and cells cultured for 24 h in RPMI sup-
plemented with 10% FCS before activation as described above.
Reagents and antibodies
All reagents were commercially obtained and of analytical
grade. The following antibodies were obtained from Cell Sig-
naling Technology: anti-mouse/human LC3B (2775); anti-
mouse/human ATG16L1 (8089); anti-phospho-tyrosine anti-
body (9411); anti-mouse/human SQSTM1 (5114). Anti-human
CASP1 (sc514); and anti-human/mouse PTPN22 (sc48922)
were obtained from Santa Cruz Biotechnology. Anti ACTB/
actin b antibody was obtained from Merck/Millipore
(MAB1501), anti-mouse NLRP3 antibody was from Adipogen
(AG-20B-0014-C100), and anti-human NLRP3 antibody was
from Enzo Life Sciences (ALX-804–819-C100).
NLRP3 vector transfections
pcDNA3.1 vectors expressing a FLAG-tagged WT mouse
NLRP3 (NLRP3 WT) and mouse NLRP3 with Tyr859 substi-
tuted by a Phe (NLRP3Y859F) or by a glutamate (NLRP3Y859E)
were obtained from Geneart (custom designed, described in
Ref. 9). To overexpress WT and mutated NLRP3 vectors in
BMDCs, the constructs were subcloned into a pLKO.1 vector,
and together with pMD2.G and pMCV plasmids used to pro-
duce lentiviral particles in HEK293T cells as described
previously.23
Western blot, immunoprecipitation, and Phos-tag
gel electrophoresis
For western blotting, equal amounts of protein from each lysate
were loaded on polyacrylamide gels and after separation by gel
electrophoresis blotted onto nitrocellulose membranes. Mem-
branes were incubated overnight with primary antibody,
washed 3 times with washing buffer (Tris-buffered saline
[0.2 M Tris base (Sigma-Aldrich, 10708976001) 1.5 M NaCl
(Sigma-Aldrich, S3014)] 0.05% Tween (Sigma-Aldrich, P1379),
3% milk powder (Roth, T145.3) before incubation with horse-
radish peroxidase-coupled anti-mouse, anti-rabbit or anti-goat
secondary antibodies (Santa Cruz Biotechnology, sc-2005, sc-
2030, and sc-2020, respectively) for 2 h. Immunoreactive pro-
teins were detected with a Fusion Solo S imager (Vilber Lour-
mat) using an enhanced chemiluminescence detection kit
(Witec AG, K12045).
For immunoprecipitation, samples were pre-cleared with
Sepharose G beads (GE Healthcare, 17–0618–01) and incu-
bated on a rocker overnight at 4C with 10 mg/ml anti-
PTPN22, 10 mg/ml anti-mouse NLRP3, 15 mg/ml anti-human
NLRP3 or 7 mg/ml anti-mouse/human SQSTM1 (Santa Cruz
Biotechnology, sc-25575) antibodies, before precipitation with
Sepharose G beads. After washing, the pellet was resuspended
in 1x loading buffer, boiled for 10 min at 95C, and the super-
natants loaded on polyacrylamide gels. For detection of precipi-
tated proteins, the same procedure was applied as used for
western blotting.
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To discriminate phosphorylated from nonphosphorylated
proteins, Phos-tag gels were obtained from Wako Chemicals
(304–93–521), and used according to the manufacturer’s
instructions and as described previously.39 In brief, cell lysates
or autophagosome-enriched cell fractions were separated
through 12% polyacrylamide gels containing 50 mM MnCl2
and 25 mM Phos-tag ligand. Gels were then blotted on nitrocel-
lulose membranes and proteins detected using the same meth-
ods as for western blotting.
Autophagosome enrichment
Autophagosomes were enriched as described by Gao et al.38 In
brief, cells were lysed in buffer B (0.25 M sucrose [Sigma-Aldrich,
S9378], 1 mM EDTA, 20 mM HEPES [Siga-Aldrich, H0887], pH
7.4) by passing 15 times through a 22 G needle, and centrifuged
for 10 min at 800 g to remove the nuclear fraction. The postnu-
clear fraction was incubated overnight with anti-LC3B antibody.
Autophagosomes were then precipitated using Sepharose G beads,
the pellets washed 3 times in ice-cold phosphate-buffered saline
(Sigma-Aldrich, D8662) and subsequently lysed in M-PER lysis
buffer (ThermoFisher Scientiﬁc, 78505) for further analysis.
RNA isolation and real-time PCR
Cells were suspended in 350 ml RLT buffer (Qiagen, 79216) and
total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen,
74106) according to the manufacturer’s instructions. RNA con-
centration was measured by absorbance at 260 and 280 nm.
cDNA (cDNA) synthesis was performed using a High-Capacity
cDNA Reverse Transcription Kit (Life Technologies, 4368813).
Real-time polymerase chain reaction (PCR) was performed using
FAST qPCR MasterMix for Taqman Assays (Life Technologies,
4352042) on a Fast HT7900 Real-Time PCR system using SDS
Software (Life Technologies). Measurements were performed in
triplicate, ACTB was used as an endogenous control, and results
were analyzed using the DDCT method. The real-time PCR con-
tained an initial enzyme activation step (5 min, 95C) followed
by 45 cycles consisting of a denaturing (95C, 15 sec) and an
annealing/extending (60C, 1 min) step. The used gene expres-
sion assays were all obtained from Life Technologies.
Confocal microscopy
For confocal microscopy, THP-1 cells were differentiated into
macrophages on cover slides using 100 mg/ml PMA (Sigma-
Aldrich, P1585) for 48 h, before activation with MSU for 6 h.
Antibodies used for detection of LC3B and NLRP3 were the
same as described above, goat anti-mouse Alexa Fluor 647
(ThermoFisher Scientiﬁc; A-21235) and goat anti-rabbit Alexa
Fluor 564 (ThermoFisher Scientiﬁc; A-11035) were used as sec-
ondary antibodies. Immunoﬂuorescence confocal microscopy
was performed using a CSLM SP5 Leica microscope and image
analyses performed using the LAS lite imaging software.
Statistical analyses
Data are presented as means § Standard Deviation for a series
of n experiments. Data are expressed as relative values of the
respective control groups. Statistical analysis was performed by
analysis of variance (ANOVA) followed by Student–Newman–
Keuls post hoc test and bonferroni correction where multiple
groups were compared with each other. P values < 0.05 were
considered signiﬁcant.
Abbreviations
ATG16L1 autophagy-related 16 like 1
BMDC bone-marrow derived dendritic cells
CD Crohn disease
DAMPS damage-associated molecular patterns
IBD inﬂammatory bowel disease
IRGM immunity related GTPase M
MAP1LC3B/LC3B microtubule associated protein 1 light
chain 3 b
MDP muramyl dipeptide
MSU monosodium urate
NLRP3 NLR family pyrin domain containing 3
PTPN22 protein tyrosine phosphatase, non-recep-
tor type 22
PYCARD PYD and CARD domain containing
RA rheumatoid arthritis
SLE systemic lupus erythematosus
SQSTM1 sequestosome 1
3-MA 3-methyladenene
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